bèta
Trial Radar AI

Er worden klinische studies voor Diabetes en passend bij locatie: België getoond.

Ik help u graag met vragen over gezondheidsaandoeningen, behandelingen en het vinden van klinische studies in uw buurt.
Onze zoekfunctie ondersteunt alleen Engels. Gebruik de Trial Radar AI hierboven om te zoeken en te discussiëren in andere talen, of selecteer hieronder de filters voor aandoening en locatie.
41 resultaten
 
Aandoening
Diabetes
×
 
Trefwoorden
Continue glucosemonitoring
×
 
Locatie
België
×
 
Geslacht
Allen, Vrouw
×
 
Studietitel
Status
Continue glucosemonitoring voor vrouwen met zwangerschapsdiabetes (CORDELIA) NCT06310356
Rekruterend
Define Predictors for Posttransplant Diabetes Mellitus Study (DECODE) NCT06440330
Rekruterend
Beta Cell Function in (Pre)Type 1 Diabetes NCT01402037
Onbekend
To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (DETECT) NCT06904846
Inschrijving op uitnodiging
Comparing Continuous With Flash Glucose Monitoring in Adults With Type 1 Diabetes (ALERTT1) NCT03772600
Afgerond
Comparison Between Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System and the FreeStyle Libre Flash Glucose Monitoring System NCT03602963
Afgerond
Prospective Randomized Clinical Trial Assessing the Short Term Clinical Impact of Continuous vs Flash Glucose Monitoring in Children, Adolescents and Young Adults With Type 1 Diabetes (GluMoCAY) NCT04249102
Onbekend
Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes NCT05777330
Rekruterend
The GLOW Study - The YANG System NCT04782934
Afgerond
Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients? NCT00726440
Afgerond
Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec (GLADE) NCT05434559
Afgerond
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL (FUTURE-GLARE) NCT05109520
Afgerond
Diabeloop for Kids (DBL4K) NCT03671915
Afgerond
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1) NCT02268214
AfgerondResultaten gepubliceerd
Diabeloop for Teens (DBL4T) NCT04725591
Afgerond
Proof of Concept - Identification of Patient-specific Parameters for Bolus Calculators for Type 1 Diabetes (POC-IDENTITY-1) NCT03414320
Afgerond
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice (CONNECT 1) NCT05069545
Afgerond
Smart MDI Study (CIP343) NCT06645834
Afgerond
24-uurs bewegingsgedrag bij volwassenen met diabetes type 1 (24h-MBs_T1D) NCT06425640
Rekruterend
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) NCT04880850
AfgerondResultaten gepubliceerd
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (COMBINE 1) NCT05352815
AfgerondResultaten gepubliceerd
Hyperglycemia and (Pre)Diabetes in Pediatric Renal and Liver Transplantation. (DIAB-GRAFT) NCT05464043
Afgerond
cArdiopulmonary exerCise Test Assessing Multiple bIOmarkers iN Type 1 Diabetes NCT05097339
Afgerond
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy NCT00790088
AfgerondResultaten gepubliceerd
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) NCT02414958
AfgerondResultaten gepubliceerd
CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes (MAGIC-T2D) NCT07064499
Actief, niet rekruterend
Cardiac Dysfunction in Adolescents With Type 1 Diabetes: Contribution of Daily-life Glucoregulation and Impact on Cardiorespiratory Exercise Capacity (GIIADMT1) NCT04052919
Afgerond
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5) NCT02825251
AfgerondResultaten gepubliceerd
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects NCT05597605
Afgerond
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus® NCT00391027
AfgerondResultaten gepubliceerd
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2) NCT02460978
AfgerondResultaten gepubliceerd
Single Dose Escalation Study of PF-05190457 in Healthy Volunteers NCT01247896
Afgerond
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D) (Meld-ATG) NCT04509791
Afgerond
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function NCT04628481
Beëindigd
Een onderzoek naar de werkzaamheid en veiligheid van teplizumab vergeleken met placebo bij deelnemers van 1 tot 25 jaar oud met stadium 3 type 1-diabetes (βETA PRESERVE) NCT07088068
Rekruterend
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes (SAFEGUARD) NCT07187531
Rekruterend
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes NCT01243424
AfgerondResultaten gepubliceerd
Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes (DIABIL-2) NCT02411253
Afgerond
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT) NCT03875729
AfgerondResultaten gepubliceerd
IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) NCT04524949
Beëindigd
Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes (GLUREDIA) NCT06770621
Rekruterend